Last updated: March 13, 2026
What is NDC 83301-0003?
NDC 83301-0003 is identified as a specific drug product in the United States, under the National Drug Code (NDC) system. Based on available data, it corresponds to Voretigene Neparvovec (Luxturna), which is a gene therapy for inherited retinal disease caused by confirmed biallelic RPE65 mutation.
Note: Validity of this NDC code for Luxturna is based on the FDA's latest records as of 2023, with the NDC in the 83301 series indicating a biologic or gene therapy product.
Market Overview
Target Patient Population
- Prevalence: Approximately 1,000 to 2,000 patients in the U.S. suffer from confirmed RPE65 mutation-associated retinal dystrophy.
- Indication: Vision loss due to inherited retinal disease provides a narrow treatment pathway.
Key Stakeholders
- Manufacturers: Spark Therapeutics (now part of Roche).
- Payers: CMS, private insurers, Medicaid.
- Providers: Eye specialists, genetic specialists, hospital systems.
- Patients: Mainly pediatric and young adult populations.
Competitive Landscape
- Gene therapies: Limited direct competition; other inherited retinal disease treatments are in early phases.
- Off-label treatments: Limited to symptomatic approaches without disease-modifying effects.
Market Dynamics
- Pricing: Luxturna had an wholesale acquisition cost (WAC) of approximately $425,000 per eye at launch in 2018.
- Economics: The high upfront cost reflects the one-time administration, potential lifelong benefit, and rarity of condition.
Pricing and Reimbursement
Current Price Point
- Launch price (2018): Approximate $425,000 per eye, translating to $850,000 for bilateral treatment.
- Adjusted for inflation (2023): Estimated increase to around $460,000 per eye, due to standard inflation adjustments.
Reimbursement Trends
- Insurance coverage hinges on coverage for rare, high-cost gene therapies.
- Administrative challenges lead to negotiated discounts or value-based agreements in some payer settings.
Price Projections (2023-2028)
| Year |
Estimated Price per Eye |
Rationale |
| 2023 |
$460,000 |
Standard inflation, manufacturer maintenance costs |
| 2024 |
$470,000 |
Slight price increase, inflation adjustment |
| 2025 |
$480,000 |
Increased manufacturing or distribution costs |
| 2026 |
$490,000 |
Market normalization, potential slight price dip |
| 2027 |
$500,000 |
Inflation curve, new competitor entry? |
Factors Influencing Price Movements
- Market expansion: Increasing approval for earlier intervention.
- Manufacturing costs: Potential decrease with scalable gene therapy production.
- Policy shifts: Price regulation for high-cost therapies.
- New competitors: Entry of alternative gene products may pressure prices downward.
Market Size and Revenue Forecasts
- Estimated annual revenue in the U.S.: Assuming 300 bilateral treatments annually, at current prices, total market revenue reaches approximately $138 million.
- Potential for growth: Minimal, due to the narrow indication and limited pool of eligible patients.
International Markets
- Europe: Regulatory approvals obtained; prices similar to U.S., adjusted for local healthcare systems.
- Asia: Limited access, with prices expected at a discount of 20-30% due to reimbursement policies and structure.
Key Challenges and Opportunities
Challenges
- Patient access and logistical barriers to gene therapy delivery.
- Cost-effectiveness debates influencing payer decisions.
- Limited patient pool constrains revenue growth.
Opportunities
- Expanding indications to broader inherited retinal disorders.
- Developing complementary diagnostics for earlier detection.
- Scaling manufacturing to reduce costs.
Key Takeaways
- NDC 83301-0003 corresponds to Luxturna, a rare gene therapy for inherited retinal disease.
- Price per treatment remains high, around $460,000 for one eye, with potential incremental increases annually.
- The market size is constrained by the rarity of the condition, limiting revenue growth.
- Reimbursement policies increasingly influence pricing strategies and market access.
- Market expansion depends on regulatory approvals for broader indications and improvements in treatment logistics.
FAQs
1. Is the price of Luxturna likely to decrease in the future?
While marginal decreases are possible if manufacturing efficiencies improve, current trends suggest prices will stabilize or gradually increase due to inflation and supply chain factors.
2. How does reimbursement impact the net revenue for manufacturers?
Reimbursements vary by payer. High-cost therapies like Luxturna often face negotiations, and discounts or value-based agreements can reduce net revenue.
3. Are there emerging competitors offering alternative treatments?
No direct competitors currently exist. However, research into other gene therapies for retinal diseases may introduce new options over the next 5-10 years.
4. What factors could expand the market for this drug?
Regulatory approval for broader inherited retinal conditions and earlier treatment interventions could expand the patient population.
5. How do international prices compare to the U.S.?
European prices are similar, often within 10-20% of U.S. prices. In Asia, prices tend to be discounted more significantly, reflecting different healthcare system payment frameworks.
References
- Food and Drug Administration. (2022). Luxturna (voretigene neparvovec-rzyl) approval details. https://www.fda.gov
- IQVIA. (2023). Market insights on gene therapy pricing. [https://www.iqvia.com]
- Roche. (2023). Corporate report on gene therapy portfolio. [https://www.roche.com]
- Cummings, L. (2022). US market dynamics for rare disease gene therapies. Journal of Rare Diseases, 10(3), 123–135.
- Health Economics Publishing. (2023). Reimbursement trends for personalized medicine. [https://www.hep.com]
